Advanced Search

Display
per page
  Report Title Date Provider Type Pgs Price

Mesoblast Ltd: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.

This report is essential reading for any serious investor, providing comprehensive financial information on a company's perfo...

30 Jul 2016 Reuters Investment Profile 12 $20.00

Mesoblast Ltd: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.

This report is essential reading for any serious investor, providing comprehensive financial information on a company's perfo...

30 Jul 2016 Reuters Investment Profile 12 $20.00

Wright Investors Service Comprehensive Report for Mesoblast Ltd

Quantitative analyses of financial statements (Income Statement, Balance Sheet and Sources of Capital), extensive ratio table...

30 Jul 2016 Wright Reports 60 $75.00

Thomson Reuters Stock Report - Mesoblast Ltd (MSB-AU)

StockReports+ gathers Thomson Reuters independent research, ratings and market data into a single report that optimizes the i...

29 Jul 2016 Thomson Reuters Stock Report 11 $25.00

Mesoblast Limited - Appendix 4C - Quarterly Report for Entities Admitted on the Basis of Commitments

29 Jul 2016 irasia.com 5 $58.00

ValuEngine Rating and Forecast Report for MESO

Advanced academic research that brings you superior investment strategies in an actionable format. The most comprehensive and...

24 Jul 2016 ValuEngine, Inc. 11 $25.00

MESOBLAST LTD (MESO=US) - SHORT AND LONG TERM FORECASTS FOR ACTIVE TRADERS

"www.pechala.com, the world's largest market forecasting firm with subscribers in 83 different countries provide forecasts of...

23 Jul 2016 Pechala's Reports 2 $25.00

Mesoblast Limited (MSB) - Financial Analysis Review

Mesoblast Limited (MSB) - Financial Analysis Review Summary Mesoblast Limited (Mesoblast) is a regenerative medicine company ...

19 Jul 2016 GlobalData 46 $300.00

MESOBLAST - TEVA RETURNS RIGHTS TO CARDIOVASCULAR PROGRAMME

Teva has relinquished all rights to cardiovascular applications of Mesoblast’s mesenchymal precursor cell (MPC) technology, a...

08 Jul 2016 Edison Investment Research 15 $10.00

Mesoblast Limited - Mesoblast Provides Update on Heart Failure Trial and Funding of Clinical Operations

01 Jul 2016 irasia.com 3 $35.00